Your browser doesn't support javascript.
loading
Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice.
Li, Xiang; Lan, Xu; Wang, Grace; Liu, Yi; Zhao, Ke; Lu, Shan-Zheng; Xu, Xiao-Xi; Shi, Gang-Gang; Ye, Kui; Zhang, Bao-Ren; Zhao, Yi-Ming; Han, Hong-Qiu; Du, Cai-Gan; Ichim, Thomas E; Wang, Hao.
Afiliación
  • Li X; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin, China.
  • Lan X; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin, China.
  • Wang G; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Liu Y; Department of Genetics, College of Basic Medical Science, Tianjin Medical University, Tianjin, China.
  • Zhao K; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Lu SZ; Department of Anorectal Surgery, People's Hospital of Hunan Province, First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, China.
  • Xu XX; Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, China.
  • Shi GG; Department of Colorectal Surgery, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Ye K; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin, China; Department of Vascular Surgery, Tianjin Fourth Central Hospital, Tianjin, China.
  • Zhang BR; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin, China.
  • Zhao YM; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin, China.
  • Han HQ; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Du CG; Department of Urologic Sciences, the University of British Columbia, Vancouver, British Columbia, Canada; Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.
  • Ichim TE; Immune Advisors LLC, San Diego, California, USA.
  • Wang H; Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin, China. Electronic address: hwangca272@hotmail.com.
Transl Oncol ; 11(4): 890-899, 2018 Aug.
Article en En | MEDLINE | ID: mdl-29793087
ABSTRACT

INTRODUCTION:

The tumor cells could escape from the immune elimination through the immunoediting mechanisms including the generation of immunosuppressive or immunoregulative cells. By contrast, allograft transplantation could activate the immune system and induce a strong allogenic response. The aim of this study was to investigate the efficacy of allogenic skin transplantation in the inhibition of tumor growth through the activation of allogenic immune response.

METHODS:

Full-thickness skin transplantation was performed from C57BL/6 (H-2b) donors to BALB/c (H-2d) recipients that were receiving subcutaneous injection of isogenic CT26 colon cancer cells (2 × 106 cells) at the same time. The tumor size and pathological changes, cell populations and cytokine profiles were evaluated at day 14 post-transplantation.

RESULTS:

The results showed that as compared to non-transplant group, the allogenic immune response in the skin-grafting group inhibited the growth of tumors, which was significantly associated with increased numbers of intra-tumor infiltrating lymphocytes, increased populations of CD11c+MHC-classII+CD86+ DCs, CD3+CD4+ T cells, CD3+CD8+ T cells, and CD19+ B cells, as well as decreased percentage of CD4+CD25+Foxp3+ T cells in the spleens. In addition, the levels of serum IgM and IgG, tumor necrosis factor (TNF)-α and interferon (IFN)-γ were significantly higher within the tumor in skin transplant groups than that in non-transplant group.

CONCLUSIONS:

Allogenic skin transplantation suppresses the tumor growth through activating the allogenic immune response, and it may provide a new immunotherapy option for the clinical refractory tumor treatment.